Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 February 2023 | Story Kekeletso Takang | Photo Supplied
Michelle De Lange
UFS School of Accountancy Lecturer, Michelle de Lange, aced the recent Chartered Global Management Accountants Board exam, obtaining second position.

Michelle de Lange, accredited Accounting Lecturer in the School of Accountancy at the University of the Free State (UFS), finished second in the world at the recent Chartered Global Management Accountant (CGMA) Board Examination. With only one point between De Lange and the first candidate, she aced the challenging exam.    

Having obtained fourth position in the world for the 2019 CIMA Gateway exam, De Lange was determined to outdo herself.

The Chartered Institute of Management Accountants (CIMA) is the world’s largest global professional management accounting body to offer training and qualification in management accountancy. As designation holders, members get to showcase their skills and experience to a global audience, while upholding professionalism and promoting continuous learning. 

De Lange, who holds another professional accreditation from the South African Institute of Chartered Accountants (SAICA), coordinates the BCom Honours in Management Accounting programme, which is CIMA-aligned for postgraduate students. For De Lange, the greatest reward is the realisation of the impact she is making on her students through strategic vision.  

Having worked in the private sector and later joining the UFS as an Assistant Director at Finance back in 2016, De Lange believed that something was missing; that there was more to give. In 2018 she moved to the School of Accountancy, taking on her new role as Lecturer. “I wanted to make a difference and be significant. This motivated my move to lecturing,” she says. 

Her passion for teaching extends beyond the lecture hall. De Lange pays it forward by supporting students through a hands-on approach and ensuring that assessments are CIMA-aligned. 

The School of Accountancy in the Faculty of Economic and Management Sciences is proud of De Lange and her achievements. 

Becoming a CGMA requires discipline. De Lange is grateful for the support she received in preparation for the board exam, in particular from her husband Francois, who was “always understanding and encouraging”. 

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept